- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
- Interventions
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 913–936
of 12,739
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- adenovirus-p53 transduced dendritic cell (DC) vaccine, 1-methyl-d-tryptophan, Laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Cachexia
- Interventions
- GSK2881078, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 99 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Overland Park, Kansas • Baltimore, Maryland
- Conditions
- Erectile Dysfunction
- Interventions
- DA-8159
- Drug
- Lead sponsor
- Dong-A PharmTech Co., Ltd.
- Industry
- Eligibility
- 19 Years to 75 Years · Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 15
- States / cities
- Huntsville, Alabama • Beverly Hills, California • Laguna Woods, California + 12 more
- Conditions
- Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Tazemetostat, Abiraterone/prednisone, Enzalutamide
- Drug
- Lead sponsor
- Epizyme, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 16
- States / cities
- San Diego, California • Denver, Colorado • Port Saint Lucie, Florida + 12 more
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- Casodex, Axumin, Salvage Radiation, Axumin
- Drug · Radiation
- Lead sponsor
- Cancer Center of Irvine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Chronic Kidney Diseases
- Interventions
- Placebo, KBP-5074
- Drug
- Lead sponsor
- KBP Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 652 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 65
- States / cities
- Foley, Alabama • Huntsville, Alabama • Mesa, Arizona + 47 more
- Conditions
- Prostate Cancer
- Interventions
- walnuts, usual diet, phone counseling with dietitian
- Other
- Lead sponsor
- Stephen Freedland
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostatic Neoplasms, Castration-Resistant, Neoplasms by Histologic Type, Neoplasms, Prostate, Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Neoplasms, Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms, Neoplasms by Site, Prostatic Disease, Salivary Gland Cancer, Salivary Gland Tumor, Adenoid Cystic Carcinoma, Salivary Duct Carcinoma, Mucoepidermoid Carcinoma, Acinic Cell Tumor
- Interventions
- P-PSMA-101 CAR-T cells, Rimiducid
- Biological · Drug
- Lead sponsor
- Poseida Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 10
- States / cities
- Duarte, California • San Diego, California • San Francisco, California + 6 more
- Conditions
- Hyperparathyroidism, Secondary
- Interventions
- Etelcalcetide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 44 more
- Conditions
- Healthy Volunteers
- Interventions
- AZD8683, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 130 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Renal Cell Carcinoma
- Interventions
- Belzutifan, Zanzalintinib
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- San Francisco, California • Mineola, New York • New York, New York + 3 more
- Conditions
- Sickle Cell Disease, Chronic Kidney Disease, Pulmonary Hypertension
- Interventions
- Erythropoietin and Hydroxyurea
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cardiovascular Injury, Prostate Carcinoma
- Interventions
- Magnetic Resonance Imaging, Exercise Intervention, Perfusion Magnetic Resonance Imaging, Spectroscopy, Laboratory Biomarker Analysis
- Procedure · Behavioral · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Stress Urinary Incontinence
- Interventions
- Cough Test following Sling Surgery
- Procedure
- Lead sponsor
- Michigan Institution of Women's Health PC
- Other
- Eligibility
- 21 Years to 89 Years · Female only
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Dearborn, Michigan
- Conditions
- Cirrhosis, Ascites, Hepatorenal Syndrome, Acute Kidney Injury
- Interventions
- OCE-205, Placebo
- Drug
- Lead sponsor
- Ocelot Bio, Inc
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Benign Prostatic Hyperplasia, Prostate Carcinoma
- Interventions
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Male only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Prostate Cancer
- Interventions
- Cabazitaxel XRP6258, Abiraterone acetate, Prednisone 5 mg
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- San Francisco, California • New Haven, Connecticut
- Conditions
- Prostate Cancer
- Interventions
- Relugolix, Leuprolide Acetate
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 387 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 108
- States / cities
- Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 83 more
- Conditions
- Acute Kidney Injury
- Interventions
- Study Physician/Advance Practice Provider, Nurse Navigator, Pharmacist, Patient Education
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Weston, Florida + 3 more
- Conditions
- Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
- Interventions
- ixabepilone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- pazopanib hydrochloride, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, pharmacogenomic studies
- Drug · Other · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Decatur, Illinois • Harvey, Illinois + 1 more
- Conditions
- Chronic Kidney Disease, Hepatic Impairment
- Interventions
- BAY3283142
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- PTSD
- Interventions
- Methylphenidate, Placebo
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- San Diego, California